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A combination of genes and a unique human genome that comprises
46 complete DNA sequences and uses thereof.
Abstract
The present invention relates to the discovery of an isolated genetic
composition and a combination of isolated nucleic acid sequences
that can confer a resistance to Human Immunodeficiency Virus
(HIV). This invention provides useful tools for research into HIV
infection and for the development of diagnostics, screening assays,
and drug discovery.
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CLAIMS
What is claimed is:
1. An isolated genetic composition comprising:
a first nucleic acid sequence comprising SEQ ID NO. 1
(Chromosome 1);1
a second nucleic acid sequence comprising SEQ ID NO. 2
(Chromosome 2);
a twenty-second nucleic acid sequence comprising SEQ ID NO. 22
(Chromosome 22);
a twenty-third nucleic acid sequence comprising SEQ ID NO. 23 (X
chromosome);
a twenty-fourth nucleic acid sequence comprising SEQ ID NO. 24
(Chromosome 1);2
a forty-sixth nucleic acid sequence comprising SEQ ID NO. 46 (Y
chromosome).
2.
A combination of isolated nucleic acid sequences comprising
SEQ ID NOs: P1-P 10.
3.
An immortalized human cell line comprising the genetic
composition of Claim 1.
DESCRIPTION
BACKGROUND OF INVENTION
1. Field of the Invention

The present invention relates to in vitro and in vivo studies of
the infective processes of the Human Immunodeficiency Virus (HIV)
and to the development of screening assays, diagnostics, anti-HIV
therapeutics, and preventive measures. Human white blood cells
1. SEQ ID NO: 1 is the complete DNA sequence of chromosome 1 and the
sequence is hypothetically disclosed in the written description.

2. Since each body cell has two sets of chromosomes, there are actually 46

nucleic acid sequences, SEQ ID NOs 1-46 that comprise the complete nuclear

genome.
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whose outer membranes display the human CD4 receptor are
normally susceptible to infection by HIV. The present invention is
noteworthy because this identified genome provides LILV resistance
even in the presence of the human CD4 receptor. The identification
of this genome, gene combination, and stable cell line provides
noteworthy new tools to explore the intracellular mechanisms of
resistance to HIV replication and its infective processes. The HIV
infection
process
begins
with
attachment
of human
immunodeficiency virions to human cell membranes, followed by
the take-over of a cell's protein synthesis machinery by the inserted
viral genome.
2. RelatedBackgroundArt
Although other individuals have demonstrated resistance to
HIV, the present invention includes an immortalized human cell line
that will facilitate research and development into anti-HIV therapies
such as gene replacement therapy. Although drug therapy has
prolonged the lives of many who are able to tolerate a strict regime
of powerful protease inhibitors and/or reverse transcription
inhibitors, greater understanding of individual resistance provided by
this invention will significantly increase therapeutic and preventive
treatments and efforts to limit an epidemic threat to the well-being of
millions of potential and existing AIDS patients.
SUMMARY OF THE INVENTION
Therefore, an object of the present invention is to provide a
stable human cell line whose cells contain an HIV resistant genome
and a gene combination (P1-P10) that confers heightened EHV
resistance.
DETAILED DESCRIPTION OF THE INVENTION
The present invention relates to a combination of genes and to a
unique human genome (hereinafter the Dolly Genome) that
comprises 46 complete DNA sequences. The Dolly Genome was
isolated and sequenced from an individual who is completely
resistant to HIV infection and resistant to developing AIDS. Thus,
the Dolly Genome represents a valuable diagnostic, screening assay,
and research resource to combat deadly HIV infection and AIDS.
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A cell line (CL100) carrying the Dolly Genome has been
developed from tissue samples obtained from the individual
completely resistant to HIV. CL100 can grow indefinitely in vitro.
Thus, it is a continuous source of the Dolly Genome.
A combination of genes P1-P10, with corresponding SEQ. ID.
NOs. P1-P10, was also isolated from the Dolly Genome. One or
more genes in combination P confer a dominant trait, i.e., only one
copy is needed and thus useful for gene therapy. Although gene
combination P does not completely confer HIV resistance, it
increases the resistance of cells and animals that carry this gene.
EXAMPLES
The following examples illustrate selected aspects of the present
invention, yet the offering of these specific examples is in no way
intended to limit the scope of the invention as defined by the claims.
Example 1
The genome of an uninfected individual at risk for infection is
extracted from white cells from a whole-blood sample and compared
to the Dolly genome to determine the degree of HIV susceptibility.
Example 2
Gene region P1-P10 of an uninfected individual at risk for
infection is isolated from a whole-blood sample and compared to the
P1-P10 sequence to ascertain the degree of HIV susceptibility.
The above genome and gene combination have been deposited
under the terms of the Budapest Treaty in the following International
Deposition Authority.
Name: National Institute of Bioscience and Cytology
Address: HG C-9361 on May 12, 1999

